Welcome to Cost Plus Med Tech. We provide medical, veterinary, and wellness products.
(713) 542-1009

iHealth vs. CorDx TyFast Flu A/B & COVID-19 Test

As the COVID-19 pandemic continues to affect global health, the need for accurate and rapid diagnostic tests remains paramount. Two popular options on the market are the iHealth COVID-19/Flu A&B Rapid Test and the CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test. In this article, we’ll compare and contrast these two tests, focusing on critical factors such as accuracy, usability, and overall value, while highlighting the superior features of the CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test.

Overview of iHealth COVID-19/Flu A&B Rapid Test

Intended Use

The iHealth COVID-19/Flu A&B Rapid Test is designed for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens. This test is authorized for non-prescription home use with self-collected anterior nares nasal swab specimens from individuals aged 14 years or older, or with adult-collected anterior nasal swab specimens from individuals two (2) years or older. The test provides results in about 15 minutes.

Ease of Use

One of the main selling points of the iHealth test is its ease of use:

  1. Swab: Insert the swab into the nostril and collect the sample.
  2. Mix: Mix the swab in the provided sample processing solution.
  3. Drip: Squeeze drops of the solution into the test device.
  4. Wait: Read the results after 15 minutes.

Limitations

Despite its simplicity, the iHealth test has several limitations:

  • Lower Sensitivity: Antigen tests, including the iHealth test, have a higher chance of giving false negative results compared to molecular tests.
  • Serial Testing Requirement: For more accurate results, serial testing is recommended, which necessitates purchasing additional tests.
  • Not as Comprehensive: The iHealth test does not differentiate between SARS-CoV and SARS-CoV-2 viruses, and it is not intended to detect influenza C antigens.

Overview of CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test

Intended Use

The CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test is a lateral flow immunochromatographic assay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen. It is specifically designed for anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19, within the first five days of symptom onset.

Principle of the Test

The CorDx test uses highly sensitive monoclonal antibodies to detect SARS-CoV-2 nucleocapsid protein and influenza A and B proteins. The test strip enclosed in a cassette housing is comprised of the following components: sample pad, reagent pad, reaction membrane, and absorbent pad.

Internal and External Quality Control

The CorDx TyFast test has built-in controls to ensure accuracy:

  • Internal Quality Control: Each test has a built-in control region that confirms the test has been performed correctly.
  • External Quality Control: Recommended for use with each new lot, shipment received, and new untrained operators.

Serial Testing

For the CorDx test, serial testing should be performed over three days with at least 48 hours between tests. If the initial test is negative but symptoms persist, subsequent tests are recommended to increase the chance of accurate results.

Superior Features

The CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test stands out due to its higher sensitivity and specificity compared to typical antigen tests like the iHealth test. Additionally, it offers the following advantages:

  • Multi-analyte Capability: Offers simultaneous detection of SARS-CoV-2, influenza A, and influenza B in a single test.
  • Broad Detection Range: Capable of detecting various SARS-CoV-2 variants and different strains of influenza A and B, providing broad applicability.
  • Stringent Quality Controls: Includes both internal and external quality control measures for high accuracy.
  • Clinical Performance: Established based on a large number of clinical specimens, making it a reliable option for rapid testing.

Detailed Comparison

Accuracy and Sensitivity

iHealth Test:

  • Accuracy: Moderate; higher chance of false negatives due to lower sensitivity.
  • Sensitivity: Lower compared to molecular tests and the CorDx test.
  • Performance Data: Limited performance data, especially with emerging variants.

CorDx TyFast Test:

  • Accuracy: High; robust internal and external controls ensure reliable results.
  • Sensitivity: Higher than typical antigen tests, comparable to molecular testing methods.
  • Performance Data: Extensive; tested against a broad range of variants and strains, ensuring comprehensive detection.

Usability and Convenience

iHealth Test:

  • Ease of Use: Simple, user-friendly steps suitable for home testing.
  • Read Time: Quick results in 15 minutes.
  • Serial Testing: Required for accurate diagnosis, necessitating multiple tests.

CorDx TyFast Test:

  • Ease of Use: Slightly more complex but with clear, step-by-step instructions.
  • Read Time: Takes about 10 minutes for results.
  • Serial Testing: Encouraged for symptomatic individuals; designed to be used in healthcare settings, ensuring professional oversight.

Overall Value

iHealth Test:

  • Cost: Generally lower, but costs can add up due to the need for serial testing.
  • Availability: Widely available for home use without prescription.

CorDx TyFast Test:

  • Cost: Slightly higher, but justified by higher accuracy and quality controls.
  • Availability: Limited to settings certified under CLIA, ensuring professional administration and oversight.

Limitations and Considerations

iHealth Test:

  • False Negatives: Higher chance, particularly in low viral load scenarios.
  • Limited Scope: Does not differentiate between SARS-CoV and SARS-CoV-2 or detect influenza C.

CorDx TyFast Test:

  • Access: Requires CLIA certification, limiting its use to professional settings.
  • Slightly Complex: More steps involved, but manageable with professional administration.

Conclusion: Why CorDx TyFast Stands Out

While both the iHealth and CorDx TyFast Flu A/B & COVID-19 tests offer valuable diagnostic tools in the fight against respiratory infections, the CorDx TyFast test clearly stands out. Its higher sensitivity and specificity, combined with robust quality controls, multi-analyte capability, and extensive performance data, make it a superior choice for accurate and reliable testing.

The iHealth test may offer convenience for home use, but its lower sensitivity and requirement for serial testing diminish its overall value. For those seeking comprehensive, accurate, and dependable results, the CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test is the clear winner.

By ensuring more accurate detection of SARS-CoV-2, influenza A, and influenza B, the CorDx test not only aids in timely diagnosis but also helps in effectively managing and controlling the spread of these respiratory infections. In professional healthcare settings, where accuracy is paramount, the CorDx TyFast test proves to be an invaluable tool, making it the preferred choice for clinicians and patients alike.